LXEO

Lexeo Therapeutics' stock has experienced price fluctuations, positive clinical data releases, financial results and financing activities, and regulatory and operational updates. The stock price has seen both increases and decreases, influenced by factors such as positive interim clinical data for LX2020 and LX2006, the closing of a $154 million equity financing, and FDA comparability approval for LX2006 manufacturing.